Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 1.00 |
| ▸ | PPARD | Q03181 | 5/20 | 1.00 |
| ▸ | PPARA | Q07869 | 5/20 | 1.00 |
| ▸ | F7 | P08709 | 5/20 | 1.00 |
| ▸ | F3 | P13726 | 5/20 | 1.00 |
| ▸ | TERT | O14746 | 3/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | FABP4 | P15090 | 3/20 | 1.00 |
| ▸ | TOP1 | P11387 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | DUSP3 | P51452 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22608051 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL22608057 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL22608055 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL20577298 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL25424711 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL20975500 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| Vaccenic Acid SCHEMBL25298899 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL25289881 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| Palmitoleic Acid SCHEMBL25293293 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL20577296 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112174811-A | High-efficiency high-purity extraction process of nervonic acid, namely cis-15-tetracosenic acid | 菏泽中禾健元生物科技有限公司 | 2021-01-05 | — | — | CN | claimed |
| US-20240277618-A1 | SOLID COMPOSITION | UNIVERSITY OF CENTRAL LANCASHIRE (GB) | 2024-08-22 | — | — | US | disclosed |
| US-11839687-B2 | Solid composition | UNIVERSITY OF CENTRAL LANCASHIRE (GB) | 2023-12-12 | — | — | US | disclosed |
| CN-105503580-B | A kind of extraction separation method of nervonic acid | 江西青春康源制药有限公司 | 2017-07-21 | — | — | CN | disclosed |
| EP-1146855-A4 | THERAPEUTIC DELIVERY USING COMPOUNDS SELF-ASSEMBLED INTO HIGH AXIAL RATIO MICROSTRUCTURES | UNIV WASHINGTON (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1146855-A1 | THERAPEUTIC DELIVERY USING COMPOUNDS SELF-ASSEMBLED INTO HIGH AXIAL RATIO MICROSTRUCTURES | University of Washington (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000037046-A1 | THERAPEUTIC DELIVERY USING COMPOUNDS SELF-ASSEMBLED INTO HIGH AXIAL RATIO MICROSTRUCTURES | UNIVERSITY OF WASHINGTON (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-1997018840-A2 | THERAPEUTIC DELIVERY USING COMPOUNDS SELF-ASSEMBLED INTO HIGH AXIAL RATIO MICROSTRUCTURES | UNIVERSITY OF WASHINGTON (US) | 1997-05-29 | — | — | WO | disclosed |
| US-5194448-A | Such as multiple sclerosis | CRODA INTERNATIONAL PLC (GB) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839687-B2 | Solid composition | LIPA, LIPC, NPC1L1 | PPARG 269/4885PPARD 658/4885PPARA 304/4885 |
| US-20240277618-A1 | SOLID COMPOSITION | LIPA, LIPC, NPC1L1 | PPARG 269/4885PPARD 658/4885PPARA 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.